Kornimate/medical-research-clean huggingface dataset:
study of neural responses induced by antidepressant effects

Conditions: Major Depressive Disorder

Summary: the proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.

over the past decade, neuroimaging tools have rapidly advanced the field of neural biomarkers of treatment response in depression. still, despite obvious scientific progress in this field, the ability to implement neuroimaging biomarkers of antidepressant treatment response in clinical trial settings is lacking. in order to objectively assess the neural bases of treatment response in depression, the investigators will use a "real-time neurofeedback fmri task", specifically designed to record and modulate mood improvement by providing neurofeedback in the context of the administration of an antidepressant treatment. in a pilot study, positive neurofeedback during the administration of the drug was associated with significant acute mood improvement and increased blood oxygen level dependent (bold) responses in the rostral anterior cingulate cortex (racc), a common neural target of antidepressant treatments. the central hypothesis is that antidepressant effects in depression are mediated by increased neural activity in the racc (aim1), which can be used in clinical trials of antidepressant treatment to predict antidepressant effects (aim 2) and assess the effect of antidepressant treatment on antidepressant-induced racc neural responses (aim 3). the results obtained from this project are expected to have an important impact on our ability to understand the cognitive and neural mechanisms implicated in antidepressant treatment responses in patients with depression, as well as on the ability to implement neuroimaging biomarkers of treatment response in the clinical trial settings.

Eligibility criteria:
inclusion criteria: * a man or woman age of 18 or older. * currently experiencing a depressive episode as part of major depressive disorder. * able to tolerate lying still on your back for 60 minutes at a time. * have had no more than one failed antidepressant trial of adequate dose and duration. * have been antidepressant medication-free for at least 21 days prior to collection of imaging data (5 weeks for fluoxetine) exclusion criteria: * are currently taking any psychiatric medication, or any potentially augmenting or sedative drugs. * have a history of inadequate response/tolerability to escitalopram; or history of resistant depression * pregnant or breastfeeding or plan to become pregnant over the duration of the study. * have a history (lifetime) of psychotic depressive, schizophrenic, bipolar, schizoaffective, or other axis i psychotic disorders. * meet criteria for substance dependence in the last 6 months, except nicotine, or substance abuse in the last 2 months. * have a medical condition that contradicts treatment with escitalopram. * are currently receiving psychotherapy or any other treatment for your depression.

Keywords: depression neuroimaging biomarkers mdd neurofeedback
3d-printed implant overdentures

Conditions: Edentulous Mouth

Summary: a randomized clinical trial (rct) was designed. fourteen completely edentulous participants were randomly allocated into two equal groups. all participants received two implants in the inter-foraminal area with ball attachments. participants in the control group were rehabilitated with conventionally manufactured polymethyl methacrylate (pmma) maxillary complete denture and mandibular implant overdentures while participants in intervention group received digital light processed (dlp)-printed photo-polymerizable pmma nextdent maxillary complete denture and mandibular implant overdentures. follow-up appointments were scheduled at 3,6, and 12 months where data of oral health impact profile 19(ohipedent19) was used to assess the ohrqol (oral health related quality of life). in addition, denture retention was measured using digital force gauge device. data were collected and statistically analyzed.


Eligibility criteria:
inclusion criteria: * completely edentulous * ranging in age from 50 to 65 years * angle's class i skeletal relationship, normal facial symmetry. * adequate quantity of bone (class iv -vi ) and quality (classes 1 - 3 ) in the mandibular inter-foraminal area to accommodate standard implants of at least 11 mm length and 3.7 mm diameter * appropriate inter-arch space of at least 15 mm (class i ) to accept all types of tested dentures exclusion criteria:metabolic disorders affecting osseointegration such as hepatic disorders * osteoporosis and diabetes mellitus. * temporomandibular disorders, anticoagulant therapy or bleeding disorders * sharp mandibular residual ridge or flabby tissues * neuromuscular disorders, and class ii and iii angle's classification skeletal relationship * smokers and patients on chemotherapy or radiotherapy or suffering from psychiatric conditions
comparison of surgical treatment options for primary congenital and developmental glaucomas

Conditions: Primary Congenital Glaucoma; Developmental Glaucoma

Summary: newborn and children can be affected by two subgroups of this disease: (1) primary congenital glaucoma (pcg) or (2) developmental glaucoma (dg). the primary aim of this study is to compare the santen preserflo implant to trabeculectomy in pcg and dg patients as second surgery after failed trabeculotomy or goniotomy.

glaucoma is a chronic, progressive disease, leading to blindness if untreated or insufficiently treated. it is characterized by a loss of optic nerve fiber and a glaucomatous optic disc excavation and, a corresponding pattern of visual field loss. newborn and children can be affected by two subgroups of this disease: (1) primary congenital glaucoma (pcg) or (2) developmental glaucoma (dg). pcg and dg are treated surgically, either by goniotomy or by trabeculotomy as first approach, and not with topical hypotensive medications. whenever these procedures have failed, the subsequent surgical procedure is usually trabeculectomy with mitomycin c or the implantation of a glaucoma drainage device. however, there is a lack of evidence regarding the "optimal" surgical approach after failed goniotomy/trabeculotomy. optimal treatment in this young group of patients with a long life expectancy is crucial to prevent blindness, allow them to participate in a "normal" school and work environment, and to minimize disease burdens for these patients and their families as well as to minimize costs for society. consequently, there is the desire to find a procedure with a superior success rate and even fewer or less severe complications compared to trabeculectomy. recently, the santen preserflo was introduced. the results proved fewer complications and comparable efficacy to trabeculectomy, according results presented at scientific meetings. yet, there are no published studies to compare the both procedures. the primary aim of this study is to compare the santen preserflo implant to trabeculectomy in pcg and dg patients.

Eligibility criteria:
inclusion criteria: * minors younger than 18 years of age with a diagnosis of primary congenital glaucoma (pcg) or developmental glaucoma (dg) will be included * participants must have had a failed trabeculotomy or goniotomy (once or twice) or one 360° trabeculotomy. exclusion criteria: * individuals with eye pathologies other than glaucoma or, who underwent intraocular surgery within the last 6 months will not be included. * patients who will not be willing to proceed with the entire follow-up of 6 months, or whose legal representative did not sign the informed consent will not be enrolled.

Keywords: glaucoma primary congenital glaucoma developmental glaucoma
kitasato pci registry

Conditions: Acute Coronary Syndrome; STEMI - ST-segment Elevation Myocardial Infarction; NSTEMI - Non-ST-Segment Elevation Myocardial Infarction; Atherosclerosis; Coronary; Ischemic; Stable Angina

Summary: the kitasato pci registry is a single-center, observational, prospective study. this study aims to investigate the impact of characteristics in clinical manifestation, patients' background, procedure of percutaneous coronary intervention (pci), and pre/post pci culprit/nonculprit lesion observed by intra-coronary imaging modality on clinical outcomes.

subjects who underwent pci are eligible in this registry. the analysis for clinical characteristics, pci procedural characteristics and findings of intra-coronary imaging including optical coherence tomography (oct) and intravascular ultrasound (ivus) is conducted. subjects are clinically followed up to 5 years after the pci.

Eligibility criteria:
inclusion criteria: * patients who underwent pci exclusion criteria: * patients who did not agree to participate in the registry
t cell validation study using blood samples from subjects with recent onset type 1 diabetes mellitus

Conditions: Type 1 Diabetes Mellitus

Summary: type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when t cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. although it is known that t cells are important mediators of the disease, progress in the development of reliable t cell assays has been modest. the purpose of this study is to learn which t cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

the t cell validation study is designed to determine the ability of t cell assays to identify differences in responses from participants with type 1 diabetes compared to normal control subjects, and to compare four different laboratory tests which examine t cells to determine whether the measurements are quantitatively reproducible. antibody assays that confirm the presence of type 1 diabetes will be evaluated including: diabetes biochemical autoantibody assay (anti-gad65, anti-ica512, anti-insulin) and islet cell autoantibody testing; genetic testing (deoxyribonucleic acid \[dna\] and human leukocyte antigen \[hla\]) will also be done to learn more about the t cell assays. the following t cell assays will be conducted in individuals with type 1 diabetes, as well as those without type 1 diabetes: * cellular immunoblot testing * t cell proliferation assay * tetramer assay * cytokine elispot assay

Eligibility criteria:
inclusion criteria: to be eligible, individuals with type 1 diabetes must be: * diagnosed with type 1 diabetes within one year of first study visit * 8-35 years of age at time of first visit * weigh \> 40 kg (88 lbs) at time of first visit * individuals who will serve as control subjects who do not have type 1 diabetes cannot have a first degree or second degree relative with type 1 diabetes. exclusion criteria: individuals must not: * have any major illness * be taking any steroid medications * if female, should not be pregnant or breastfeeding.

Keywords: type 1 diabetes juvenile onset diabetes insulin dependent diabetes t1d
clinical value of plasma humanin in acute kidney injury

Conditions: Acute Kidney Injury

Summary: the goal of this observational study is to assess the clinical value of humanin in acute kidney injury. the main questions it aims to answer are:whether humanin can be a novel marker for predicting aki researchers will compare humanin concentration in healthy people to see if humanin can be a novel marker for predicting aki

acute kidney injury (aki) is a clinically critical condition manifested by a sharp decline in kidney function, with approximately 13.3 million people diagnosed with aki each year in hospital worldwide and associated with 1.7 million deaths. according to global multi-center research data, the total incidence of aki in hospital is as high as 21%, and the incidence of acute kidney injury in hospitalized patients in china is 0.99%\~11.6%. aki increases the risk of long-term chronic kidney disease (ckd) and end-stage renal disease (esrd), and has a very high long-term mortality rate. the diagnosis of aki is mainly based on blood creatinine or urine output, and the current kdigo criteria are used, but blood creatinine is a very insensitive indicator, so in the past 20 years, scholars have been exploring biological markers that are more sensitive than blood creatinine and urine output. humanin is a mitochondrial polypeptide containing 24 amino acids. it was first identified in alzheimer's disease patients in 2001. studies have shown that humanin has a strong mitochondrial protective effect in neurodegenerative diseases, cardiovascular diseases, diabetes, male infertility, cancer and other diseases, and its mechanism may be related to anti-apoptosis, anti-inflammation, regulation of autophagy and maintenance of mitochondrial homeostasis, because humanin can function through autocrine, paracrine or endocrine forms, so it can be detected in the blood. studies have shown that humanin expression in serum or plasma of patients with diabetes and coronary heart disease is declined. in our previous study, the investigators found that humanin was elevated in plasma in a mouse model of aki with sepsis. the goal of this observational study is to assess the clinical value of humanin in acute kidney injury. the main questions it aims to answer are:whether humanin can be a novel marker for predicting aki

Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years of age, male or female； * patients with aki: patients with acute kidney injury who meet the definition of kdigo guidelines； * control group: from healthy physical examination population, physical examination blood routine, urine routine, liver function, kidney function, glycated hemoglobin and other indicators are normal； * the patient's baseline medical record data is complete, including liver and kidney function, urine protein level, blood creatinine value, etc； * consent to enrollment and sign informed consent； exclusion criteria: * age\< 18 years； * baseline data were missing
pharmacokinetic of alirocumab sar236553 (regn727) administered subcutaneously at 3 different injection sites in healthy subjects

Conditions: Hypercholesterolemia

Summary: primary objective: to assess the relative bioavailability of a single subcutaneous dose of alirocumab sar236553 (regn727) administered at 3 different injection sites in healthy subjects. secondary objectives: * to assess the pharmacodynamic effect of a single subcutaneous dose of alirocumab sar236553 (regn727) on serum low-density lipoprotein cholesterol and other lipids and apolipoproteins. * to assess the safety of a single subcutaneous dose of alirocumab sar236553 (regn727). * to assess the immunogenicity of a single subcutaneous dose of alirocumab sar236553 (regn727).

total duration of the study per subject is about 15 weeks.

Eligibility criteria:
inclusion criteria: healthy subjects. exclusion criteria: healthy subjects with history or presence of clinically relevant illness. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
safety and efficacy study of first-line treatment with ql1706 plus chemotherapy in extensive-stage small cell lung cancer

Conditions: Extensive-stage Small-cell Lung Cancer

Summary: this is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (pk) profile, and immunogenicity of ql1706 plus carboplatin and etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. subjects participate voluntarily and sign informed consent. 2. histologically or cytologically confirmed es-sclc (per the veterans administration lung study group \[valg\] staging system) 3. no prior systemic treatment for es-sclc 4. eastern cooperative oncology group performance status of 0 or 1 5. measurable disease, as defined by recist v1.1 6. adequate hematologic and end organ function exclusion criteria: 1. active or untreated central nervous system (cns) metastases as determined by computed tomography (ct) or magnetic resonance imaging (mri) evaluation 2. active, known or suspected autoimmune disease 3. history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, radiation pneumonia requiring steroid treatment or evidence of active pneumonitis on screening chest ct scan. history of radiation pneumonitis in the radiation field (fibrosis) is permitted. 4. positive test result for human immunodeficiency virus (hiv) 5. active hepatitis b or hepatitis c 6. significant cardiovascular disease
pilot study of text message brief interventions for problem drinkers

Conditions: Alcohol Dependence

Summary: this study will provide a pilot test of two different text message interventions for problem drinkers. participants will be recruited using a general population telephone survey. participants in a control group (who will not receive text messages) will be compared to participants who receive one of two different types of text message packages (12 text messages sent once per week in each) - a series of personalized feedback text messages or a series of consciousness raising test messages (i.e., messages that keep the thought of cutting down on their drinking in the participants' mind). participants in the three different conditions will be followed-up in three months time to assess changes in drinking. it is predicted that participants who receive either of the text message packages will report reduced drinking as compared to those participants in the control condition who do not receive any text messages.


Eligibility criteria:
inclusion criteria: * resident of ontario * 19 years of age or over * have consumed alcohol in the one month prior to the telephone survey. * a score of 8 or over on the alcohol use disorders identification test (audit) * are willing to participate in follow-up at three months exclusion criteria: •none
the role of cgrpand nociceptin in migraine

Conditions: Migraine; Headache

Summary: the release of the neuropeptide calcitonin gene-related peptide (cgrp) is thought to play a causative role in migraine. nociceptin immunoreactivity and orl-1 mrna have been detected in human trigeminal ganglia where it was co-localized with cgrp. it may play a role in migraine pathogenesis. we are collecting the blood samples of migraineurs for analysis of these neuropeptides.

the release of the neuropeptide calcitonin gene-related peptide (cgrp) is thought to play a causative role in migraine. nociceptin immunoreactivity and orl-1 mrna have been detected in human trigeminal ganglia where it was co-localized with cgrp. it may play a role in migraine pathogenesis. we are collecting the blood samples of migraineurs for analysis of these neuropeptides.

Eligibility criteria:
inclusion criteria: patients with headache - exclusion criteria: fever, congenital anomaly, cns organic lesions -

Keywords: migraine cgrp nociceptin
aerosolized versus intravenous colistin-based antimicrobial regimens in hospitalized covid-19 patients with bacterial coinfection: a randomized controlled trial

Conditions: Secondary Bacterial Infection in COVID-19 Patients

Summary: secondary bacterial pathogen infection has been demonstrated to aggravate covid-19 clinical outcomes. bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making covid-19 patient management difficult. as a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have covid-19 infection.


Eligibility criteria:
inclusion criteria: * covid-19 patients with secondary gram-negative bacterial infections exclusion criteria: * patients with resistant bacterial strains to polymyxins * patients less than 18 years
endometriosis impact on oocyte quality

Conditions: Endometriosis

Summary: the aim of this study is to evaluate the impact of endometriosis on folliculogenesis and oocyte quality. to do so, a metabolomic approach will be conducted in order to analyze the follicular fluid. this evaluation will be completed by a transcriptomic analysis from the cumulus cells of the oocyte. the normal and pathological oocyte cohort after controlled ovarian stimulation will be also characterized by identifying the oocyte leading to live birth.

endometriosis pathophysiology remains under controversy. among the various issues raised, that of his involvement in an implantation failure related to an alteration of the endometrium is advanced by some authors. for others, infertility would be linked to an alteration of the oocyte quality responsible for embryonic development impairment leading to a lack of implantation. several research groups have also mentioned the association of the two mechanisms. the oocyte quality evaluation is also subject to controversy. indeed, its morphological approach remains the most commonly used in routine at the ivf laboratory. however, this tool remains limited and to date, no correlation between oocyte morphology and art outcomes have been established. in this context, there is a real need to use functional approaches such as genomics, transcriptomics, proteomics and metabolomics. however, the clinical validation and application of these functional tools have to be evaluated from a human pathology model such as endometriosis.

Eligibility criteria:
inclusion criteria: group 1: case a. womens with endometriosis i. deep endometriosis without ovarian localisation ii. deep endometriosis associated with ovarian localisation iii. isolated ovarian localisation b. male partner with normal sperm parameters group 2 : control 1. womens with isolated tubal factor 2. male partner with normal sperm parameters exclusion criteria: * other pathologies responsible for female infertility * altered sperm parameters * male or female viral risk * oocyte or sperm donation

Keywords: endometriosis metabolomics transcriptomics follicular fluid cumulus cells oocyte quality
is analgesic effect of low dose ketamine-midazolam the same as morphine

Conditions: Closed Multiple Fractures of Upper and Lower Limbs

Summary: the investigators assessed the effects of low-dose iv ketamine-midazolam versus morphine on pain control in trauma patients with closed limb fracture(s); and also compared the incidence of adverse events (mainly cardio pulmonary ) between two groups.

this prospective, single blind, noninferiority trial randomized consecutive ed patients aged 18 to 60 years to two groups: receiving either 300-500 mcg ketamine plus 0.03 mg midazolam, or 0.05 to 0.1 mg morphine. visual analogue score and adverse events were carefully verified during an interval of 30 minutes. two hundreds, thirty six patients were selected, among whom were 207 males (87.3%), and 29 females (12.2%). the average age was 29±2, with extremes of 60 years and 18 years.the patients were divided into two groups: g1: 116 patients receiving ketamine-midazolam and g2: 120 patients receiving morphine alone.

Eligibility criteria:
inclusion criteria: 1. between 18 and 60 years 2. patients with closed limb fracture(s) 3. vas score of at least 6 exclusion criteria: 1. acute pulmonary infection 2. previous coronary artery diseases,acs,congestive heart failure, 3. suspected aortic dissection 4. history of uncontrolled hypertention or blood pressure \> 140/90mmhg 5. brain injury with focal neurological deficit or loss of consciousness 6. central nervous system mass lesion,hydrocephalus, or other states with increased intracranial pressure 7. glaucoma and acute globe injury 8. history of porphyria 9. previous hyperthyroidism or thyroid hormone replacement 10. pregnancy or laction 11. major psychiatric disorder 12. previous allergic reaction to the agents administered in the study 13. patient declined to provide written informed conse

Keywords: ketamine, midazolam, morphine, visual analogue score